Calibre One Appoints Jed Donnelly to Enhance Life Sciences Expertise for Redhill Biopharma.
- Calibre One appoints Jed Donnelly as Partner to enhance expertise in healthcare and life sciences sectors.
- Donnelly's extensive experience in biopharmaceutical recruitment strengthens Calibre One's leadership in executive search.
- His appointment reflects Calibre One's commitment to supporting innovation in healthcare and life sciences.
Calibre One Strengthens Life Sciences Expertise with New Partner Appointment
Calibre One, a leading global executive search firm, announces the strategic appointment of Jed Donnelly as Partner, effective June 24, 2025. Based in Boston, Donnelly brings over 20 years of extensive experience in retained executive search, particularly within the biopharmaceutical and life sciences sectors. His background includes successfully conducting searches for a wide array of clients, from venture-backed startups to publicly traded companies, with a focus on therapeutics, diagnostics, and life sciences investment. This appointment is significant as it highlights Calibre One's commitment to enhancing its capabilities in the healthcare sector, especially as the industry continues to expand and evolve.
Donnelly's impressive credentials include his tenure as a founding Partner at a boutique executive search firm dedicated to life sciences, where he led impactful searches for over a decade. He also served as Vice President of Research at another firm, facilitating more than 350 placements. This extensive experience equips him with a strategic and insight-driven approach to executive recruitment, making him an invaluable asset to Calibre One. Tom Barnes, Managing Partner at Calibre One, emphasizes that Donnelly's dual perspective as both an investor and operator uniquely positions him to contribute to the firm’s growth in the life sciences sector, which is currently witnessing significant advancements and opportunities.
In addition to his professional achievements, Donnelly holds a J.D. from Georgetown University Law Center and a B.A. in Biology from Colby College. His active involvement in the community, particularly as President of the Board for Special Surfers—a nonprofit that provides surfing opportunities for individuals with special needs—demonstrates his commitment to social responsibility and community engagement. Donnelly's appointment not only strengthens Calibre One's leadership in executive search but also reinforces its dedication to supporting innovation in healthcare and life sciences.
In other industry news, Theravance Biopharma, Inc. recently announces that Viatris Inc. has secured regulatory approval from China's National Medical Products Administration for YUPELRI® (revefenacin), marking a significant milestone as the first once-daily nebulized long-acting muscarinic antagonist approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in China. This approval not only enhances Theravance's financial outlook with a one-time payment from Viatris but also positions the company for potential future earnings through sales-based milestones and royalties.
Additionally, Theravance continues to advance its registrational study for ampreloxetine, aimed at treating symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy. With promising results from previous studies, the ongoing Phase 3 CYPRESS study holds the potential for further development and regulatory application, showcasing the dynamic progress within the biopharmaceutical landscape.
